RTSN logo

RETENSION PHARMACEUTICALS IN

RTSNNASDAQ
πŸ† #4284 by market capEarnings Feb 17US Equity
$10.59β–Ό $2.41 (βˆ’18.51%)
Market closed Β· at close
πŸ””
Track RTSN
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 18.5%
7dβ–Ό 13.8%
14dβ–Ό 2.3%
30dβ–Ό 29.4%
ytdβ€”
1yβ€”
🏦Market Cap
$40M
Small Cap
πŸ“ˆRevenue Growth (YoY)
β€”
πŸ“ŠGross Margin
β€”
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
β€”
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$9.61 – $12.49
52-Week Range
$9.23 – $18.64
Volume (shares)
6,437
Avg Volume (shares)
β€”
Shares Outstanding
3.8M
Next Earnings
2027-02-17

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
β€”
P/E Ratio
β€”
P/S Ratio
β€”
EPS (TTM)
β€”
Dividend Yield
β€”
RTSN logo

RETENSION PHARMACEUTICALS IN

RTSN
Financial Trends

Financial history unavailable.

StockOtter Β· stockotter.space

About RETENSION PHARMACEUTICALS IN

Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its product, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. The company was founded by Eric Keller and Paul Sweetnam in 2023 and is headquartered in Falls Church, VA.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates